Article,

Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

, , , , , , , , and .
PLOS ONE, 15 (11): 1-6 (November 2020)
DOI: 10.1371/journal.pone.0242184

Abstract

Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.

Tags

Users

  • @fordham1

Comments and Reviews